Literature DB >> 12037047

Development of a sensitive and specific enzyme-linked immunosorbent assay for detecting and quantifying CMY-2 and SHV beta-lactamases.

Andrea M Hujer1, Malcolm G P Page, Marion S Helfand, Bethany Yeiser, Robert A Bonomo.   

Abstract

Polyclonal rabbit antibodies against SHV-1 and CMY-2 beta-lactamases were produced and characterized, and enzyme-linked immunosorbent assays (ELISAs) were developed. Immunoblots revealed that the anti-SHV-1 antibody recognized SHV-1 but did not recognize TEM-1, K-1, OXA-1, or any AmpC beta-lactamase tested. The anti-CMY-2 antibody detected Escherichia coli CMY-2, Enterobacter cloacae P99, Klebsiella pneumoniae ACT-1, and the AmpC beta-lactamases of Enterobacter aerogenes, Morganella morganii, and Citrobacter freundii. No cross-reactivity of the anti-CMY-2 antibody was seen against laboratory strains of E. coli possessing TEM-1, SHV-1, K-1, or OXA-1 beta-lactamases. Operating conditions for performing ELISAs were optimized. Both anti-CMY-2 and anti-SHV-1 antibodies detected picogram quantities of purified protein in ELISAs. The reactivity of the anti-CMY-2 antibody was tested against a number of AmpC beta-lactamases by assaying known quantities of purified enzymes in ELISAs (AmpC beta-lactamases of M. morganii, C. freundii, E. coli, and E. cloacae). As the homology to CMY-2 beta-lactamase decreased, the minimum level needed for detection increased (e.g., 94% homology recognized at 1 ng/ml and 71% homology recognized at 10 ng/ml). The ELISAs were used to assay unknown clinical isolates for AmpC and SHV beta-lactamases, and the results were confirmed with PCR amplification of bla(AmpC) and bla(SHV) genes. Overall, we found that our ELISAs were at least 95% sensitive and specific for detecting SHV and AmpC beta-lactamases. The ELISA format can facilitate the identification of AmpC and SHV beta-lactamases and can be used to quantify relative amounts of beta-lactamase enzymes in clinical and laboratory isolates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12037047      PMCID: PMC130713          DOI: 10.1128/JCM.40.6.1947-1957.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  A standard numbering scheme for the class A beta-lactamases.

Authors:  R P Ambler; A F Coulson; J M Frère; J M Ghuysen; B Joris; M Forsman; R C Levesque; G Tiraby; S G Waley
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

2.  Selection and application of antibodies modifying the function of beta-lactamase.

Authors:  E Bibi; R Laskov
Journal:  Biochim Biophys Acta       Date:  1990-08-17

3.  Preliminary experiment for detection of penicillinase by enzyme-linked immunosorbent assay and western blotting technique.

Authors:  S Kamata; A Ohkawa; O Ito; N Kakiichi; K Komine; T Matsunaga; M Hayashi; M Sugiyama; H Otsuka; S Ura
Journal:  J Vet Med Sci       Date:  1992-04       Impact factor: 1.267

4.  Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.

Authors:  S Lin; M Thomas; D M Shlaes; S D Rudin; J R Knox; V Anderson; R A Bonomo
Journal:  Biochem J       Date:  1998-07-15       Impact factor: 3.857

Review 5.  Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics.

Authors:  A A Medeiros
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

Review 6.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

7.  Systematic mutagenesis of the active site omega loop of TEM-1 beta-lactamase.

Authors:  J F Petrosino; T Palzkill
Journal:  J Bacteriol       Date:  1996-04       Impact factor: 3.490

8.  Evolution of antibiotic resistance: several different amino acid substitutions in an active site loop alter the substrate profile of beta-lactamase.

Authors:  T Palzkill; Q Q Le; K V Venkatachalam; M LaRocco; H Ocera
Journal:  Mol Microbiol       Date:  1994-04       Impact factor: 3.501

9.  Immunoreactivity of five monoclonal antibodies against the 37-kilodalton common cell wall protein (PsaA) of Streptococcus pneumoniae.

Authors:  J Crook; J A Tharpe; S E Johnson; D B Williams; A R Stinson; R R Facklam; E W Ades; G M Carlone; J S Sampson
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

10.  Site-saturation mutagenesis and three-dimensional modelling of ROB-1 define a substrate binding role of Ser130 in class A beta-lactamases.

Authors:  J M Juteau; E Billings; J R Knox; R C Levesque
Journal:  Protein Eng       Date:  1992-10
View more
  25 in total

1.  Clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases: prevalence of CTX-M-3 at a hospital in China.

Authors:  Hui Wang; Swathi Kelkar; Weiyuan Wu; Minjun Chen; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

2.  Antibody mapping of the linear epitopes of CMY-2 and SHV-1 beta-lactamases.

Authors:  Andrea M Hujer; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  SHV-129: A Gateway to Global Suppressors in the SHV β-Lactamase Family?

Authors:  Marisa L Winkler; Robert A Bonomo
Journal:  Mol Biol Evol       Date:  2015-11-03       Impact factor: 16.240

4.  Reply to Frère: Covalent trapping and bacterial resistance to ceftazidime.

Authors:  Krisztina Papp-Wallace; Robert A Bonomo
Journal:  J Biol Chem       Date:  2013-09-13       Impact factor: 5.157

5.  N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam.

Authors:  Marion J Skalweit; Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

6.  Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.

Authors:  Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton; Marion J Skalweit
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

7.  Molecular epidemiology of Escherichia coli producing extended-spectrum beta-lactamases isolated in Rome, Italy.

Authors:  Alessandra Carattoli; Aurora García-Fernández; Paola Varesi; Daniela Fortini; Serena Gerardi; Adriano Penni; Carlo Mancini; Alessandra Giordano
Journal:  J Clin Microbiol       Date:  2007-10-24       Impact factor: 5.948

8.  Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Andrea M Hujer; Magdalena A Taracila; Robert A Bonomo; Brad Spellberg
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

9.  Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.

Authors:  Andrea Endimiani; Yohei Doi; Christopher R Bethel; Magdalena Taracila; Jennifer M Adams-Haduch; Alexandra O'Keefe; Andrea M Hujer; David L Paterson; Marion J Skalweit; Malcolm G P Page; Sarah M Drawz; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-02-09       Impact factor: 3.162

10.  Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?

Authors:  Markus Hilty; Parham Sendi; Salome N Seiffert; Sara Droz; Vincent Perreten; Andrea M Hujer; Robert A Bonomo; Kathrin Mühlemann; Andrea Endimiani
Journal:  Int J Antimicrob Agents       Date:  2013-01-10       Impact factor: 5.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.